<DOC>
	<DOCNO>NCT03054532</DOCNO>
	<brief_summary>This multi-center , open-label , phase II study durvalumab combination lenalidomide treatment relapsed/refractory NK/T-cell lymphoma ( NKTCL ) . The study employ 2-stage Simon Optimal design 80 % power type 1 error rate ( significance level ) 5 % . Stage 1 involve 8 patient require least 2 patient achieve primary end point overall response order proceed onto stage 2 , target enrolment 14 patient .</brief_summary>
	<brief_title>Phase II Study Durvalumab Combination With Lenalidomide Relapsed/Refractory NK-T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically proven NK/Tcell lymphoma relapse least one cycle induction chemotherapy . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 3 . Previously treat least one cycle chemotherapy include Lasparaginase gemcitabine . 4 . Must age ≥ 21 year able sign inform consent form . 5 . Adequate hematological function ( unless abnormality relate lymphoma infiltration bone marrow hemophagocytic syndrome relate NKL ) within 30 day prior sign inform consent , include : 1 . Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L 2 . Platelet count ≥ 50 x 109/L 3 . Hemoglobin ≥ 8 g/dL 6 . Must able adhere study visit schedule protocol requirement . 7 . Females childbearing potential must : 1 . Have 2 negative pregnancy test verify Study Investigator prior start study therapy . She must agree ongoing pregnancy test course study , end study therapy . This apply even patient practice complete abstinence heterosexual contact . 2 . Either commit complete abstinence heterosexual contact agree use , able comply , effective contraception without interruption , 28 day prior start study drug , study therapy ( include dose interruption ) , 28 day discontinuation study therapy . 8 . Male patient must practice complete abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption 28 day discontinuation study therapy , even undergone successful vasectomy . 9 . All patient must : 1 . Have understand study drug could potential teratogenic risk . 2 . Agree abstain donate blood take study drug , dose interruption 28 day discontinuation study therapy . 3 . Agree share study medication another person . 4 . Agree counseled pregnancy precaution risk fetal exposure . 5 . Females must agree abstain breast feed study participation 28 day discontinuation study therapy . 10 . Male subject donate sperm semen take lenalidomide , break ( dose interruption ) , least 28 day last dose lenalidomide . 1 . Concomitant use investigational agent . 2 . Known infection human immunodeficiency virus ( HIV ) . 3 . Patient know clinically active hepatitis B ; carrier hepatitis B permit need appropriate antiviral therapy regular hepatitis B DNA virus monitor advised Gastroenterologist . 4 . Subject calculate measured creatinine clearance &lt; 30 mL/minute . 5 . Neuropathy &gt; Grade 2 . 6 . Presence CNS involvement lymphoma . 7 . Myocardial infarction within 6 month prior enrolment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . 8 . Clinically significant active infection uncontrolled intercurrent illness . 9 . Pregnant lactating female . 10 . Coexistent second malignancy history prior malignancy within precede 3 year ( exclude nonmelanoma skin tumor situ carcinoma cervix ) . 11 . Any significant medical psychiatric condition might prevent patient comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>